Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Executive Director, USA
International Association for the Study of Lung Cancer (IASLC)
Aurora, CO

Roy S. Herbst, MD, PhD
Professor of Medicine
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Smilow Cancer Hospital at Yale-New Haven
Yale School of Medicine
New Haven, CT

Ramaswamy Govindan, MD
Professor of Medicine
Director, Thoracic Oncology Program
Co-Director of the Section of Medical Oncology
Washington University School of Medicine
St. Louis, MO

Fred R. Hirsch, MD, PhD
Professor, Division of Medical Oncology
University of Denver School of Medicine
Denver, CO

Susan J. Keen, RN, OCN
Thoracic Nurse Navigator
Thomas Johns Cancer Hospital
CJW Medical Center
Richmond, VA

Jim Koeller, M.S.
Professor
University of Texas at Austin
College of Pharmacy
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine
Pharmacotherapy Education & Research Center
University of Texas Health Science Center at San Antonio
San Antonio, TX

Philip C. Mack, MD, PhD
Associate Adjunct Professor
Director, Molecular Pharmacology
UC Davis Cancer Center
Sacramento, CA

Ronald. B. Natale, MD
Attending Physician
Cedars-Sinai Medical Center
Samuel Oschin Comprehensive Cancer Institute
Director of the Lung Cancer Research Program
Los Angeles, CA

Joan H. Schiller, MD
Professor & Division Chief
Hematology-Oncology
Deputy Director,
Harold C. Simmons Cancer Center
Andrea L. Simons Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Dallas, TX
Chair, Lung Committee, Eastern Cooperative Oncology Group (ECOG)

Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section
Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
UPMC Cancer Pavillion
Pittsburgh, PA

David R. Spigel, MD
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN

Heather Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

This activity is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer, including physician assistants and fellows. Lung cancer is treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to this activity for personalized therapies of lung cancer.

Based on the data identified in the Needs Assessment and Physician Practice Gap Identification and Analysis, the following Learning Objectives have been developed for these CME activities:

1. Incorporate molecular biomarkers, histology and patient clinical characteristics into strategies for devising personalized NSCLC patient therapies.
2. Understand how to collect and utilize lung tissue for conducting molecular tests to personalize systemic targeted therapies for NSCLC patients.
3. Develop new treatment algorithms for NSCLC patients in the first-line and refractory settings incorporating current and novel targeted therapies directed against existing and new targets.
4. Describe the clinical applications of anti-EGFR therapy for NSCLC patients with mutation-positive EGFR and with wild type EGFR across all lines of therapy.
5. Devise and apply strategies utilizing novel chemotherapy including multi-targeted antifolate chemotherapy for PS2 NSCLC patients, and, with strategies to decrease drug-induced side effects by using certain chemotherapy for NSCLC and SCLC.
6. Evaluate the various strategies to manage and/or prevent acquired resistance to EGFR, using novel and existing anti-EGFR and TKI therapies in combination with strategies directed against c-MET, MEK, VEGF and other biologic targets.
7. Review the existing and emerging strategies directed at angiogenesis and VEGF with or without additional biologic targets and pathways for patients with NSCLC.
8. Compare and contrast antigen-independent and antigen-specific immunotherapeutic strategies for lung cancer patients, including an orally administered immunomodulatory protein, antibodies targeting PD-1 and CTLA4, and various vaccines.
9. Recall opportunities to enroll eligible lung cancer patients in numerous ongoing clinical trials with various investigational agents for improving NSCLC outcomes and counsel appropriate patients about participation.
10. Explain the recent data showing improved overall survival in lung cancer patients by using novel bone-targeted therapy.

Based on the data identified in the Needs Assessment and Practice Gap Identification and Analysis, the following Learning Objectives have been developed for these CE activities:

1. Recall the importance of molecular biomarkers, histology and patient clinical characteristics as part of strategies for devising personalized NSCLC patient therapies.
2. Define how to collect and utilize lung tissue for conducting molecular tests to personalize systemic targeted therapies for NSCLC patients.
3. Identify new treatment algorithms for NSCLC patients in the first-line and refractory settings incorporating current and novel targeted therapies directed against existing and new targets.
4. Describe the clinical applications of anti-EGFR therapy for NSCLC patients with mutation-positive EGFR and wild type EGFR across all lines of therapy.
5. List the novel strategies utilizing novel chemotherapy including multi-targeted antifolate chemotherapy for PS2 NSCLC patients, and, with strategies to decrease drug-induced side effects by using certain chemotherapy for NSCLC and SCLC.
6. Outline the various strategies to manage and/or prevent acquired resistance to EGFR, using novel and existing anti-EGFR and TKI therapies in combination with strategies directed against c-MET, MEK, VEGF and other biologic targets.
7. Recall the existing and emerging strategies directed at angiogenesis and VEGF with or without additional biologic targets and pathways for patients with NSCLC.
8. List the antigen-independent and antigen-specific immunotherapeutic strategies for lung cancer patients, including an orally administered immunomodulatory protein, antibodies targeting PD-1 and CTLA4, and various vaccines.
9. Identify opportunities to enroll eligible lung cancer patients in numerous ongoing clinical trials with various investigational agents for improving NSCLC outcomes and counsel appropriate patients about participation.
10. Recall the recent data showing improved overall survival in lung cancer patients by using novel bone-targeted therapy.

The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Biomedical Learning Institute designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Biomedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-12-008-L01-P
Credits: 8.25 hours (0.825 ceu)
Type of Activity: Knowledge

The Biomedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The Biomedical Learning Institute designates this educational activity for 8.25 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 9 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

There is an opportunity to exhibit at this symposium. Please send an email to phillip.renner@bmli.com for more information or call 214-269-2007.

Sincere appreciation is extended to the following companies for their generous commercial support of this educational activity: